BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24023672)

  • 1. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
    Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
    PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases.
    Berger A; Venturelli S; Kallnischkies M; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Weiss TS; Lauer UM; Bischoff SC; Bitzer M
    J Nutr Biochem; 2013 Jun; 24(6):977-85. PubMed ID: 23159065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T; Prasad R; Katiyar SK
    Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
    Venturelli S; Niessner H; Sinnberg T; Berger A; Burkard M; Urmann C; Donaubauer K; Böcker A; Leischner C; Riepl H; Frank J; Lauer UM; Garbe C; Busch C
    Cell Physiol Biochem; 2018; 51(2):543-556. PubMed ID: 30458450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
    Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
    J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.
    Huang H; Liu N; Guo H; Liao S; Li X; Yang C; Liu S; Song W; Liu C; Guan L; Li B; Xu L; Zhang C; Wang X; Dou QP; Liu J
    PLoS One; 2012; 7(11):e49062. PubMed ID: 23139833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.
    Bär SI; Dittmer A; Nitzsche B; Ter-Avetisyan G; Fähling M; Klefenz A; Kaps L; Biersack B; Schobert R; Höpfner M
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35485292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
    Li F; Wang T; Wang Z; Chen X; Liu R
    Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
    Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
    Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
    Liu Q; Zhang B; Wang Y; Wang X; Gou S
    Eur J Med Chem; 2022 Feb; 229():114058. PubMed ID: 34954595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
    Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
    Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
    Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.